On September 13, 2016, Alexander M. Lesokhin, MD, discussed immunotherapy treatment options for patients with multiple myeloma, and how close we are to making these treatments available to more patients, including studies in vaccines, monoclonal antibodies, and checkpoint blockade.
Dr. Lesokhin is an assistant attending physician on the Myeloma Service and Immunotherapeutics Core and a member of the Ludwig Collaborative Laboratory at Memorial Sloan Kettering Cancer Center in New York, NY. His research focuses on the ability of cancers to evade the immune system and on developing novel treatments to reverse this process. Lesokhin leads a portfolio of clinical trials testing the clinical and immune effects of immunotherapies in blood cancers. He received his MD from the Albert Einstein College of Medicine, and then went on to complete his residency and oncology fellowship training at Columbia University Medical Center and Memorial Sloan Kettering, respectively.
This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This series is presented by Genentech and LabAnswer and its employees, with generous support from Abbvie, Celldex Therapeutics, NewLink Genetics, and Regeneron. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.
